Keywords: teva, invests, 1m, esi, cell, cure, unit
Teva invests $1M in ESI's Cell Cure unit
Article | 15 October 2007
Generic drug giant Teva Pharmaceutical Industries will invest $1.0 million in fellow Israeli firm ES Cell International's majority-owned subsidiary, Cell Cure ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
